Commodore Capital LP: ENLIVEN THERAPEUTICS INC (ELVN): Quarterly 13F Position History
As of Q1 2026, Commodore Capital LP reported 3,275,000 shares of ENLIVEN THERAPEUTICS INC (ELVN), worth $128.4M and representing 7.4% of its 13F equity book. Quarter-over-quarter share count change: 1,417,809 (-30.2%) . The position first appeared in Q1 2023 and has been disclosed across 13 13F-HR filings in Pactolio's tracked window.
- 3,275,000Shares Held (Latest Filing)
- $128.4MReported Market Value (Latest Filing)
- 7.4%Portfolio Weight (% of 13F Equity Book)
- 1,417,809Quarter-over-Quarter Share Change
- +$56.1MQuarter-over-Quarter Value Change
- 4,692,809Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 13 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 3,275,000 | 1,417,809 | -30.2% | $128.4M | 7.4% | $39.2 |
| Q4 2025 | 4,692,809 | 0 | — | $72.3M | 4.8% | $15.4 |
| Q3 2025 | 4,692,809 | 0 | — | $96.1M | 4.7% | $20.5 |
| Q2 2025 | 4,692,809 | +17,809 | +0.4% | $94.1M | 6.6% | $20.1 |
| Q1 2025 | 4,675,000 | +470,000 | +11.2% | $92.0M | 6.8% | $19.7 |
| Q4 2024 | 4,205,000 | +105,000 | +2.6% | $94.6M | 6.9% | $22.5 |
| Q3 2024 | 4,100,000 | +126,755 | +3.2% | $104.7M | 6.5% | $25.5 |
| Q2 2024 | 3,973,245 | 0 | — | $92.9M | 6.3% | $23.4 |
| Q1 2024 | 3,973,245 | +1,071,429 | +36.9% | $69.9M | 4.7% | $17.6 |
| Q4 2023 | 2,901,816 | 0 | — | $40.2M | 3.5% | $13.8 |
| Q3 2023 | 2,901,816 | +553,544 | +23.6% | $39.6M | 4.6% | $13.7 |
| Q2 2023 | 2,348,272 | +616,907 | +35.6% | $47.9M | 5.4% | $20.4 |
| Q1 2023 | 1,731,365 | — | — | $37.9M | 5.8% | $21.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Commodore Capital LP first disclose a ELVN position in 13F-HR filings?
Commodore Capital LP first reported ENLIVEN THERAPEUTICS INC (ELVN) on its 13F-HR filing for the period ending 2023-03-31 (Q1 2023). The position has appeared on 13 reported quarters within Pactolio's tracked window.
What was Commodore Capital LP's most recent quarter-over-quarter share-count change in ELVN?
Between Q4 2025 and Q1 2026, Commodore Capital LP reduced its ELVN position by 1,417,809 shares (-30.2%), leaving 3,275,000 shares at a market value of $128.4M.
Does the implied price-per-share represent Commodore Capital LP's cost basis in ELVN?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.